Archive | 4D Meets AI RSS feed for this section

Congratulations to the 4D Meets AI Innovator’s Pitch Challenge Winners!

25 Mar

By Joey Wong, Investor Research Analyst, LSN

Life Science Nation (LSN)’s 4D Meets AI partnering conference successfully concluded last Friday, March 19. Over the two-day event, LSN featured seven exceptional startup companies at the intersection of AI and life science through the Innovator’s Pitch Challenge (IPC).

Each company was featured on a dedicated landing page that hosted their pitch video and supplementary materials, and they participated in a live Q&A session with a panel of investor pitch judges. Conference attendees were able to visit these landing pages or join the live Q&A sessions, and they were encouraged to vote for their favorite IPC companies before the end of the conference.

Many thanks to all the IPC companies for their hard work promoting their technologies and to the pitch judges who supported each session with their feedback. Each company was judged on their supporting materials, as well as their live pitch and Q&A. Congratulations to Huma.AI and Thrive Bioscience for winning their sessions!

Huma.ai is a venture-backed healthcare AI company. It’s ML-enabled, questions and answers-driven knowledge automation platform turns domain experts into their own data scientists so that they can make real-time decisions driven by data. According to its customers, Huma.ai has cracked the Holy Grail.

Thrive is commercializing a family of instruments and software that provide previously unavailable data, imaging, analytics, and automation for cell culture, stem cell culture, and tissue culture for use in biomedical research and cell therapeutics. Thrive has recently started selling the first two instruments in the family, the CellAssist and the CellAssist 50. Both collect 1,000’s of images of live cells in culture, analyzes them, provides guidance and builds a significant database. The CellAssist 50 enables researchers to automatically and remotely image 50 plates of cells on an ongoing basis, generating large amounts of data for live cell biology. Sites include Harvard Stem Cell Institute, Center for Genomic Medicine (Massachusetts General Hospital), Stanford Stem Cell Core, University of Texas Medical Branch, as well as large and small pharma/biotech companies.

If you’re interested in the next upcoming Innovator’s Pitch Challenge, you can apply for the Digital RESI IPC taking place June 8-10. Applications close May 14!

This image has an empty alt attribute; its file name is digital-june-2021-banner-1100.png

Keep the Conversations Going

18 Mar

By Rory McCann, Marketing Manager & Conference Producer, LSN

Healthtech Partnering Week is off to the races! Digital RESI March has wrapped up with 1,000+ meetings in 3 days and leads into a triple-threat partnering experience consisting of 4D Meets AI, Access China Spring Forum (free), and Longevity, Health & Innovation taking place consecutively March 18-19.

It’s not too late to sign up and get involved in any of these three events! To learn more, visit the Healthtech Partnering Week website. Each conference offers unique opportunities suited for specific technology assets and market solutions. We hope you’ll join us and round out your RESI partnering with the full Healthtech Partnering Week experience!





Hot Mandate: Investment Arm of Hospital System Interested In Novel Applications in Digital Health

15 Mar

A investment arm of a non-profit hospital system manages a $15M fund and usually writes checks in the $1 million range. The firm will participate mostly in Series A and B rounds but is open to considering earlier stage, non-revenue generating companies with highly disruptive technologies. Currently, the firm is focused only on USA-based investment opportunities.

The firm is seeking digital health companies with technologies that can provide significant value to their hospital system. The firm is most interested in those that address their key organization priorities, which include (1) virtualization of care (i.e. telehealth), (2) operational efficiency, (3) patient and clinician experience of care. The organization is also interested in novel applications of technologies such as AI that may not impact healthcare in the short term, but may have disruptive potentials in the future. The organization is not interested in therapeutics, medical devices, or diagnostics companies.

The firm is looking to work with companies with experienced management teams. The firm does not act as a lead investor and only seeks to co-invest.

If you are interested in more information about this investor and other investors tracked by LSN, please email 4dmeetsai@lifesciencenation.com.

Hot Mandate: China-Based VC Strongly Interested In Growth-Stage Healthcare IT and AI & Big Data Applications in Life Sciences

15 Mar

Founded in 2012 and based in Shenzhen, China, a venture capital backed by 79 local corporations manages 150 million CNY fund (~21 million in USD). The firm typically takes exit in 5 to 7 years after investing. While the allocation size can largely vary, the firm mainly focuses on growth-stage companies that already have clinical data or got FDA/CFDA approved.

The firm has strong interests in novel diagnostics technologies, especially IVD, and they pay close attention to healthcare IT, and AI & big data applications in life science. The third hot spot for the frim is medical devices, especially surgical robots. The novel service platform with the technologies of cell or gene area. The firm has a strong focus on companies that can provide solutions on cardiovascular disease, oncology, orthopedics, central nervous system disorders, and Endocrine system disorders.

The firm invests globally but prefers companies with a Chinese angle and the series entrepreneurs.

If you are interested in more information about this investor and other investors tracked by LSN, please email 4dmeetsai@lifesciencenation.com.

Hot Mandate: Corporate Venture Capital Invests in Customer-Centered Health Strategies, Including AI Applications in Healthcare

15 Mar

A venture capital arm of a multination corporation has several offices in the USA including Boston, MA and Menlo Park, CA. The firm has approximately $2B AUM and has invested $200M in 40 companies in 2016. The investment size varies, depending on the opportunity. The firm is actively seeking new investment opportunities in the life sciences and will look globally.

The firm invests in customer-centered health strategies, which may include mobile health IT, digital health, and artificial intelligence applied to healthcare. The firm is also interested in therapeutics, particularly synthetic biology, nanotechnology, and gene therapy. The firm is opportunistic in terms of stage of development.

The firm primarily invests in life science companies with a strong and experienced management team. The firm usually takes a board seat.

If you are interested in more information about this investor and other investors tracked by LSN, please email 4dmeetsai@lifesciencenation.com.

Introducing Healthtech Partnering Week Innovator’s Pitch Challenge Finalists

11 Mar

By Claire Jeong, Chief Conference Officer, Vice President of Investor Research, Asia BD, LSN

claireLife Science Nation (LSN) is pleased to announce next week’s Healthtech Partnering Week (HPW) Innovator’s Pitch Challenge finalists. The Innovator’s Pitch Challenge is an opportunity for early-stage companies to gain additional exposure to conference attendees, pitch directly to a panel of relevant investors, and participate in a live Q&A session.

Pitching opportunities at LSN partnering events are popular events for startups and investors alike. They provide exposure and experience to the companies, while providing investors with insight into the latest technology organized by sector and interest. Check out our finalists and select a logo to learn more about their participation. Registration is still open, so don’t miss out and sign up today!

Innovator’s Pitch Challenge Finalists

 

Announcing McDermott Will & Emery HPW Workshops

11 Mar

By Gregory Mannix, Vice President International Business Development, LSN

Life Science Nation (LSN) is thrilled to welcome McDermott Will & Emery as Title Sponsor of Healthtech Partnering Week (HPW) with two live workshops accessible to registered attendees of Redefining Early Stage Investments (RESI) and 4D Meets AI.

McDermott Will & Emery has brought valuable insights to LSN’s community of early-stage fundraising companies, investors, service providers, and strategic partnerships for years, and we look forward to bringing their content to the digital stage next week. There’s still time to register for HPW – Sign up for access to McDermott Will & Emery workshops and more!

Negotiating Term Sheets: What’s Best for the Company and What’s Best for You?
Live Workshop! March 16 | 1 PM EDT (Register for RESI Access)

Instructors:

  • Nancy Briefs, President & CEO, AltrixBio, Inc.
  • David Hendren, Managing Director, Augmentum Ventures
  • Mark Mihanovic, Partner, McDermott Will & Emery
  • Aroma Sharma, Partner, McDermott Will & Emery

This interactive workshop, organized and led by McDermott Will & Emery, will provide wisdom to early-stage CEOs and management on the latest trends in term sheets, with a focus on founder and management equity opportunities. The workshop will cover common issues of concern to entrepreneurs (valuation/dilution, liquidation preference, board makeup, protective provisions, anti-dilution). Experts from the legal, investment and entrepreneurial community will discuss the interplay of financing milestones in the term sheet discussion. Learn more!

How to Go to Market: Commercializing AI-Based Health Technologies
Live Workshop! March 19 | 10 AM EDT (Register for 4D Meets AI Access)

Instructors:

  • Richie Bavasso, MBA, Co-Founder & CEO, nQ Medical Inc.
  • Carolyn Metnick, JD, Partner, McDermott Will & Emery
  • Michael Ryan, JD, Partner, McDermott Will & Emery
  • Dale Van Demark, JD, Partner, McDermott Will & Emery

This workshop, hosted by our Title Sponsor McDermott Will & Emery, will focus on the various options for and the legal considerations involved with commercializing AI-based healthcare technologies, including regulatory and data strategies. Learn about the range of options, from R&D use to consumer products, from leading members of McDermott’s digital health practice and companies that have blazed the trail. Learn more!

%d bloggers like this: